CVS Restores Zepbound Coverage and Adds Eli Lilly’s New Obesity Pill to Commercial Formulary
CVS Restores Zepbound Coverage — and Adds Eli Lilly’s New Obesity Pill to the Mix
For nearly a year, millions of Americans with commercial insurance had a hole in their weight management options. One of the most effective medications on the market — Zepbound — was dropped from CVS Caremark’s standard formulary. Wegovy got preferred status. Patients got left behind.
That changes now.
CVS Health announced on May 28, 2026, that it is restoring coverage of Zepbound effective October 1, 2026, and is adding coverage for Eli Lilly’s newly approved obesity pill, Foundayo (generic name: orforglipron), effective June 1, 2026. Both Lilly’s medications and Novo Nordisk’s Wegovy will be listed as co-preferred options on CVS Caremark’s standard commercial formulary — a template that covers approximately 25 to 30 million Americans, depending on plan sponsor participation.
Let that sink in: 25 to 30 million people on standard commercial plans will now have access to both drug classes as preferred options. That’s not a rounding error. That’s a systemic shift.
What Changed — and Why It Matters
Last year, CVS made a cost-driven decision to drop Zepbound and make Wegovy the sole preferred GLP-1 option. The move created a bottleneck: patients who responded better to tirzepatide — the active ingredient in Zepbound — were either forced to switch, pay full price out of pocket, or go without. At roughly $1,000 per month without insurance, that last option wasn’t realistic for most people.
The reformulation of CVS’s formulary strategy reflects two realities: competition is working, and the weight management category is too large and too clinically important to leave to a single manufacturer.
Eli Lilly’s entry with Foundayo — an oral GLP-1 receptor agonist (not an injection) — represents a new dimension in treatment access. For patients who have gym phobias about needles, or who travel frequently and can’t manage cold-chain storage, an oral option changes the calculus entirely. Orforglipron has shown meaningful weight loss in clinical trials, and its oral delivery mechanism makes it a genuine challenger to the injectable class.
The Savings Angle
CVS projects 10 to 15 percent additional savings across the weight management category with this dual-preferred structure. That makes sense: when you have two effective drug classes competing for formulary placement, manufacturers have incentive to negotiate harder on price. CVS is betting that having both Eli Lilly and Novo Nordisk in the co-preferred tier gives them leverage they didn’t have when they went all-in on Wegovy.
This is also a reaction to the broader market dynamics. GLP-1 medications for weight loss represent one of the fastest-growing cost categories in U.S. commercial pharmacy benefits. Managed care is learning to play both manufacturers against each other — and that’s good for the system, even if the process is slower than patients would like.
What This Means for Patients
If you have commercial insurance through a plan that uses the CVS Caremark standard formulary template, you may now have access to:
- Zepbound (tirzepatide) — restored as a preferred option as of October 1, 2026
- Foundayo (orforglipron) — newly covered as of June 1, 2026
- Wegovy (semaglutide) — remains preferred
All three as co-preferred. That’s meaningful.
That said, one important caveat remains: plan sponsors — your employer or your union — can still opt out of covering GLP-1 medications for weight loss entirely. CVS has structured this as a template benefit, not a mandate. So the first question to ask your HR department or benefits broker is simple: “Does our plan follow the CVS Caremark standard formulary?” If yes, you likely have access. If your plan sponsors opted out of the weight management category, you may be out of luck — regardless of what CVS lists as preferred.
Always verify coverage directly with your plan administrator before assuming.
The Clinical Bottom Line
Two observations from the office:
First, having multiple preferred options matters clinically, not just financially. Patients respond differently to different GLP-1 formulations. Some lose more weight on tirzepatide. Some tolerate semaglutide better. Some do better on an oral agent. When an insurance company limits you to one preferred medication, you’re forcing a square peg into a round hole. Co-preferred status gives both doctors and patients room to individualize treatment.
Second, orforglipron is a legitimate new entrant. It’s not a me-too drug. The oral delivery is a genuine advantage for a subset of patients who simply won’t inject themselves — and that subset is larger than many clinicians realize. Having it covered as a preferred option expands the number of people who can access effective treatment.
Key Takeaway
CVS Health has effectively reversed its 2025 formulary decision and created a dual-preferred structure for GLP-1 medications in the weight management category. Zepbound is back. Foundayo is in. And Wegovy stays. For the 25 to 30 million Americans on standard CVS Caremark commercial plans, this is meaningful progress.
Whether your specific plan follows the standard formulary is the question to answer first. Then have the conversation with your doctor about which option fits your life, your preferences, and your physiology.
We have more tools now. That’s a good thing.
Source: CVS Health formulary announcement, May 28, 2026, via CNBC.